1993
The Therapeutic Potential of Neurotrophic Factors in the Treatment of Parkinson's Disease
Lindsay R, Altar C, Cedarbaum J, Hyman C, Wiegand S. The Therapeutic Potential of Neurotrophic Factors in the Treatment of Parkinson's Disease. Experimental Neurology 1993, 124: 103-118. PMID: 8282068, DOI: 10.1006/exnr.1993.1181.Peer-Reviewed Original ResearchConceptsNeurotrophic factorParkinson's diseaseNeurodegenerative disordersTherapeutic agentsNeurodegenerative diseasesFetal nigral graftsTransplantation of neuronsDopamine neurotrophic factorPartial symptomatic reliefDopamine receptor agonistsNeurotrophic growth factorsPotential clinical useHuman neurodegenerative disordersAppropriate neurotransmittersObvious therapeutic strategyNeuronal lossNigral graftsSymptomatic reliefDevelopment of drugsDopaminergic neuronsNeuroprotective agentsSubstantia nigraNeuronal degenerationNeurotrophin familyDopamine neurons
1987
Clinical Pharmacokinetics of Anti-Parkinsonian Drugs
Cedarbaum J. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clinical Pharmacokinetics 1987, 13: 141-178. PMID: 3311529, DOI: 10.2165/00003088-198713030-00002.Peer-Reviewed Original ResearchConceptsAnti-parkinsonian agentsAnti-parkinsonian drugsClinical PharmacokineticsParkinson's diseaseDirect acting dopamine receptor agonistsLarge neutral amino acidsResponse fluctuationsAnti-parkinsonian actionLittle pharmacokinetic dataPharmacodynamics of levodopaTherapeutic response fluctuationsPlasma levodopa concentrationsDopamine receptor agonistsPotential drug toxicityClass of drugsMechanism of actionParkinsonian populationRenal functionPharmacokinetic considerationsUnchanged drugBrain uptakeReceptor agonistRenal excretionShort eliminationLevodopa concentrations